BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33819437)

  • 21. Dysproteinemias and Glomerular Disease.
    Leung N; Drosou ME; Nasr SH
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):128-139. PubMed ID: 29114004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.
    Ciocchini M; Arbelbide J; Musso CG
    Int Urol Nephrol; 2017 Dec; 49(12):2171-2175. PubMed ID: 28425076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment.
    Karam S; Haidous M; Dalle IA; Dendooven A; Moukalled N; Van Craenenbroeck A; Bazarbachi A; Sprangers B
    Crit Rev Oncol Hematol; 2023 Mar; 183():103926. PubMed ID: 36736510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy-associated proliferative glomerulonephritis.
    Sethi S; Rajkumar SV
    Mayo Clin Proc; 2013 Nov; 88(11):1284-93. PubMed ID: 24182705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal gammopathy of renal significance: Early diagnosis is key.
    Alonso-Titos J; Martínez-Esteban MD; López V; León M; Martin-Reyes G; Ruiz-Esteban P; Hernández D
    Nefrologia (Engl Ed); 2021; 41(5):502-513. PubMed ID: 36165133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone.
    Nasr SH; Larsen CP; Sirac C; Theis JD; Domenger C; Chauvet S; Javaugue V; Hogan JJ; Said SM; Dasari S; Vrana JA; McPhail ED; Cornell LD; Vilaine E; Massy ZA; Boffa JJ; Buob D; Toussaint S; Guincestre T; Touchard G; D'Agati VD; Leung N; Bridoux F
    Kidney Int; 2020 Mar; 97(3):589-601. PubMed ID: 32001067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report.
    Hirashio S; Satoh A; Arima T; Mandai K; Awaya T; Oshima K; Hara S; Masaki T
    BMC Nephrol; 2018 May; 19(1):108. PubMed ID: 29724182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characteristics and prognostic analysis of monoclonal gammopathy of renal significance (MGRS) in patients with IgM monoclonal gammopathy: a case series.
    Liu J; Liang D; Liang S; Xu F; Huang X; Jiang S; Hou J
    Sci Rep; 2022 Oct; 12(1):16994. PubMed ID: 36216844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance.
    Sprangers B; Hegenbart U; Wetzels JFM
    Transplantation; 2023 May; 107(5):1056-1068. PubMed ID: 36584374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.
    Said SM; Leung N; Alexander MP; Cornell LD; Fidler ME; Grande JP; Herrera LH; Sethi S; Zhang P; Nasr SH
    Kidney Int; 2020 Aug; 98(2):498-504. PubMed ID: 32622524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological characteristics of patients with paraproteinemia and renal damage.
    Tang X; Wan F; Yu J; Li X; Yang R; Zhu B
    Eur J Med Res; 2021 Jul; 26(1):68. PubMed ID: 34217367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update to the pathogenesis for monoclonal gammopathy of renal significance.
    Zuo C; Zhu Y; Xu G
    Ann Hematol; 2020 Apr; 99(4):703-714. PubMed ID: 32103323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia.
    Gutiérrez-Peredo GB; Filho JCBO; Montaño-Castellón I; Gutiérrez-Peredo AJ; Crusoé EQ; Gusmao-Flores D
    BMC Nephrol; 2022 Aug; 23(1):278. PubMed ID: 35945525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease.
    Midha S; Nadeem O; Selamet U
    Semin Nephrol; 2022 Nov; 42(6):151352. PubMed ID: 37257390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.
    Leung N; Bridoux F; Hutchison CA; Nasr SH; Cockwell P; Fermand JP; Dispenzieri A; Song KW; Kyle RA;
    Blood; 2012 Nov; 120(22):4292-5. PubMed ID: 23047823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology and management of monoclonal gammopathy of renal significance.
    Jain A; Haynes R; Kothari J; Khera A; Soares M; Ramasamy K
    Blood Adv; 2019 Aug; 3(15):2409-2423. PubMed ID: 31409583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment].
    Lysenko Kozlovskaya LV; Rameev VV; Androsova TV
    Ter Arkh; 2020 Jul; 92(6):15-22. PubMed ID: 33346488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The value of serum free light chain in differential diagnosis of monoclonal gammopathy of renal significance].
    Li C; Wen YB; Li H; Su W; Li J; Cai JF; Chen LM; Li XM; Li XW
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(30):2344-2348. PubMed ID: 28822451
    [No Abstract]   [Full Text] [Related]  

  • 39. Renal pathologic spectrum and clinical outcome of monoclonal gammopathy of renal significance: A large retrospective case series study from a single institute in China.
    Yu XJ; Zhang X; Li DY; Wang SX; Zhou FD; Zhao MH
    Nephrology (Carlton); 2020 Mar; 25(3):202-211. PubMed ID: 31301197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].
    Gödecke V; Schmidt JJ; Bräsen JH; Koenecke C; Haller H
    Internist (Berl); 2019 Jan; 60(1):10-22. PubMed ID: 30635666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.